The Biotech Growth Trust (LSE: BIOG)

Last close As at 18/05/2024


−10.00 (−1.00%)

Market capitalisation


The Biotech Growth Trust seeks capital appreciation through investing in the worldwide biotechnology industry. Performance is measured against its benchmark index, the NASDAQ Biotechnology Index (sterling adjusted).

Latest Insights

View More

Investment Companies | Update

The Biotech Growth Trust — Onwards and upwards for performance recovery

Investment Companies | Review

The Biotech Growth Trust — Historic low sector valuations

Equity Analyst

Melanie Jenner

Mel Jenner

Director, Investment Trusts

Key Management

  • Andrew Joy


  • Geoffrey Hsu

    Fund manager

  • Richard Klemm

    Fund manager

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 2.4 2.9 17.6
Relative (5.1) (5.9) 8.1
52 week high/low 1024.0p/718.0p


The Biotech Growth Trust’s (BIOG’s) two co-managers, Geoff Hsu and Josh Golomb, at global healthcare specialist OrbiMed, believe that now could be an opportune time to consider the biotech sector as it is recovering from the longest and largest absolute and relative drawdown since 2006. The sector was negatively affected by sharply rising interest rates rather than a deterioration in industry fundamentals; indeed, the managers continue to refer to a ‘golden era’ of innovation within the biotech sector. BIOG’s relative performance has been through a difficult period given its high weighting in emerging (smaller-cap) biotech stocks, which performed significantly worse than the shares of large-cap biotech businesses during the sector sell-off.



Investment Companies

UK stock market – Scope for further upside in UK large-cap stocks


Investment Companies

Listed private equity – Performing a balancing act


Investment Companies

European equities


Investment Companies

Listed Private Equity

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free